- United States
- /
- Biotech
- /
- OTCPK:TRVN
Trevena Second Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.69 loss in 2Q 2023)
Trevena (NASDAQ:TRVN) Second Quarter 2024 Results
Key Financial Results
- Net loss: US$4.89m (loss narrowed by 39% from 2Q 2023).
- US$0.23 loss per share (improved from US$0.69 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Trevena Earnings Insights
Looking ahead, revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 2.4% from a week ago.
Risk Analysis
You should learn about the 7 warning signs we've spotted with Trevena (including 5 which are significant).
Valuation is complex, but we're here to simplify it.
Discover if Trevena might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OTCPK:TRVN
Trevena
A biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders.
Medium-low and slightly overvalued.